Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$6.62 USD
+0.44 (7.12%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $6.59 -0.03 (-0.45%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.62 USD
+0.44 (7.12%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $6.59 -0.03 (-0.45%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -5.56% and 3.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals (RXRX) Soars 7.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 0% and 5.66%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Recursion (RXRX) Stock Surges 191% in 3 Months: Here's Why
by Zacks Equity Research
Recursion's (RXRX) shares rallied almost 191% over the past three months, owing to artificial intelligence-driven acquisitions and strategic collaborations to advance drug development.
Recursion (RXRX) Up on $50M NVDA Investment for AI Drug Discovery
by Zacks Equity Research
Recursion (RXRX) soars on receiving an investment worth $50 million from Nivida for drug development using artificial intelligence.
Recursion (RXRX) Up on Completing REC-994 Study Enrollment
by Zacks Equity Research
Recursion's (RXRX) shares rise as it completes patient enrollment for a mid-stage study of REC-994 to treat cerebral cavernous malformations.
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 0% and 23.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -106.67% and 79.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Bears are Losing Control Over Recursion Pharmaceuticals (RXRX), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Recursion Pharmaceuticals (RXRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Recursion Pharmaceuticals (RXRX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Recursion Pharmaceuticals (RXRX)? Wall Street Analysts Think 53.67%
by Zacks Equity Research
The mean of analysts' price targets for Recursion Pharmaceuticals (RXRX) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 2.78% and 104.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 1.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.57% and 37.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -10% and 11.98%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -164.71% and 96.51%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
IsoRay (ISR) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
IsoRay (ISR) delivered earnings and revenue surprises of 0% and 7.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -29.63% and 39.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Recursion (RXRX) Inks Neuroscience and Oncology Deal With Roche
by Zacks Equity Research
Recursion (RXRX) inks a collaboration with Roche to identify novel targets and advance medicines in areas of neuroscience and oncology indication. Shares rise.